Neptune Tech (NEPT) 0.98 $NEPT Neptune Announce
Post# of 273331
Posted On: 09/02/2016 11:04:14 PM
Neptune Tech (NEPT) 0.98 $NEPT
Neptune Announces Fourth Quarter and Fiscal Year Results
Marketwire Canada - Wed May 25, 4:01PM CDT
Positive Forward Momentum Continues
NTB.TO: 1.26 (+0.01), NEPT: 0.98 (+0.03)
Acasti Announces Fourth Quarter and Fiscal Year Results
Marketwire Canada - Wed May 25, 4:01PM CDT
LAVAL, QUEBEC--(Marketwired - May 25, 2016) - Acasti Pharma Inc. ("Acasti" or the "Corporation"
(NASDAQ:ACST)(TSX VENTURE:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia, announces its operating and financial results for the fourth quarter and fiscal year ended February 29, 2016. All amounts are in Canadian dollars.
ACST: 1.35 (+0.02), NTB.TO: 1.26 (+0.01), NEPT: 0.98 (+0.03), APO.VN: 1.720 (-0.060)
Neptune to Hold Conference Call to Discuss Fourth Quarter and Year-End Results
Marketwire Canada - Fri May 13, 7:01AM CDT
LAVAL, QUEBEC--(Marketwired - May 13, 2016) - Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company" (NASDAQ:NEPT)(TSX:NTB), announces that it will be holding a conference call on May 26, 2016 at 8:30 AM (ET) to discuss its results for the fourth quarter and year-end results ended February 29, 2016.
NTB.TO: 1.26 (+0.01), NEPT: 0.98 (+0.03)
Jan D'Alvise Appointed President & CEO of Acasti Pharma
Marketwire Canada - Thu May 12, 7:09AM CDT
Seasoned Executive in Drug Development
ACST: 1.35 (+0.02), NTB.TO: 1.26 (+0.01), NEPT: 0.98 (+0.03), APO.VN: 1.720 (-0.060)
Neptune Announces Term Loan Financing
Marketwired - Wed Apr 20, 10:15AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company" (NASDAQ: NEPT)(TSX: NTB), announces that it has signed a term loan of approximately $4 million (2.10 million GBP) with Bank and Clients PLC ("B&C" based in the UK. Under certain conditions, the loan could be increased up to $10 million (5.25 million GBP). All amounts are in Canadian dollars unless otherwise stated.
NTB.TO: 1.26 (+0.01), NEPT: 0.98 (+0.03)
Neptune Announces Preliminary Q4 Results
Marketwired - Tue Apr 05, 6:31AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company" (NASDAQ: NEPT)(TSX: NTB), announces preliminary selected results for the fourth quarter ended February 29, 2016. All amounts in Canadian dollars. The financial information in this press release excludes Acasti Pharma.
ACST: 1.35 (+0.02), NTB.TO: 1.26 (+0.01), NEPT: 0.98 (+0.03)
Nasdaq Grants Acasti Cure Period to Regain Compliance with Audit Committee Membership Requirements
Marketwire Canada - Fri Mar 25, 1:03PM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation" (NASDAQ:ACST)(TSX VENTURE:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of hypertriglyceridemia, announces that on March 22, 2016, it received a Nasdaq Deficiency Letter (the "Nasdaq Letter" confirming that the Corporation is no longer in compliance with Nasdaq Listing Rule 5605, requiring a company's audit committee to be comprised of at least three independent directors. Following the resignation of several board members on February 29, 2016, Acasti's Audit Committee is currently comprised of two independent directors.
ACST: 1.35 (+0.02), NTB.TO: 1.26 (+0.01), NEPT: 0.98 (+0.03), APO.VN: 1.720 (-0.060)
Acasti Announces Share-for-Debt
Marketwire Canada - Fri Feb 05, 4:30PM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation" (NASDAQ:ACST)(TSX VENTURE:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of hypertriglyceridemia, announces the issuance of fifty thousand class A common shares as part of a settlement agreement executed on February 5, 2016.
ACST: 1.35 (+0.02), NTB.TO: 1.26 (+0.01), NEPT: 0.98 (+0.03), APO.VN: 1.720 (-0.060)
Neptune Acquires Biodroga, Creating New Growth Platform
GlobeNewswire - Thu Jan 07, 6:07PM CST
-- Acquires privately held Biodroga, a leading turnkey dietary supplement solution provider with TTM revenues of $22M CDN
NTB.TO: 1.26 (+0.01), NEPT: 0.98 (+0.03)
Neptune to Hold Conference Call to Discuss Third Quarter Results
GlobeNewswire - Tue Jan 05, 6:50AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation" (NASDAQ:NEPT) (TSX:NTB), announces that it will be holding a conference call on January 13, 2016 at 8:30 AM (ET) to discuss its results for the third quarter ended November 30, 2015.
NTB.TO: 1.26 (+0.01), NEPT: 0.98 (+0.03)
BUYINS.NET: PRU, RLH, CTCT, NEPT, PAC, HIMX Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Dec 03, 2:42AM CST
November 27, 2015
RLH: 6.39 (-0.01), PRU: 79.49 (+0.65), HIMX: 10.51 (+0.28), NEPT: 0.98 (+0.03), PAC: 101.06 (+1.59), CTCT: 32.01 (+1.39)
Neptune Provides Business Update
GlobeNewswire - Fri Nov 06, 8:21AM CST
-- Cash levels growing - expect nutraceutical Q3 cash balance of $4.5 - $5.0 million
NTB.TO: 1.26 (+0.01), NEPT: 0.98 (+0.03)
BUYINS.NET: NEPT, SBH, AIMC, CVLT, MHH, BIB Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Fri Oct 23, 8:02AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Neptun SA (NASDAQ:NEPT), Sally Beauty Holdings Inc (NYSE:SBH), Altra Holdings Inc (NASDAQ:AIMC), CommVault Systems Inc (NASDAQ:CVLT), Mastech Holdings Inc (NYSE:MHH), ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
BIB: 45.81 (-0.22), SBH: 27.71 (+0.30), MHH: 7.72 (+0.07), CVLT: 52.25 (+0.13), AIMC: 28.72 (+0.50), NEPT: 0.98 (+0.03)
Neptune Announces Fourth Quarter and Fiscal Year Results
Marketwire Canada - Wed May 25, 4:01PM CDT
Positive Forward Momentum Continues
NTB.TO: 1.26 (+0.01), NEPT: 0.98 (+0.03)
Acasti Announces Fourth Quarter and Fiscal Year Results
Marketwire Canada - Wed May 25, 4:01PM CDT
LAVAL, QUEBEC--(Marketwired - May 25, 2016) - Acasti Pharma Inc. ("Acasti" or the "Corporation"
(NASDAQ:ACST)(TSX VENTURE:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia, announces its operating and financial results for the fourth quarter and fiscal year ended February 29, 2016. All amounts are in Canadian dollars. ACST: 1.35 (+0.02), NTB.TO: 1.26 (+0.01), NEPT: 0.98 (+0.03), APO.VN: 1.720 (-0.060)
Neptune to Hold Conference Call to Discuss Fourth Quarter and Year-End Results
Marketwire Canada - Fri May 13, 7:01AM CDT
LAVAL, QUEBEC--(Marketwired - May 13, 2016) - Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company"
(NASDAQ:NEPT)(TSX:NTB), announces that it will be holding a conference call on May 26, 2016 at 8:30 AM (ET) to discuss its results for the fourth quarter and year-end results ended February 29, 2016. NTB.TO: 1.26 (+0.01), NEPT: 0.98 (+0.03)
Jan D'Alvise Appointed President & CEO of Acasti Pharma
Marketwire Canada - Thu May 12, 7:09AM CDT
Seasoned Executive in Drug Development
ACST: 1.35 (+0.02), NTB.TO: 1.26 (+0.01), NEPT: 0.98 (+0.03), APO.VN: 1.720 (-0.060)
Neptune Announces Term Loan Financing
Marketwired - Wed Apr 20, 10:15AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company"
(NASDAQ: NEPT)(TSX: NTB), announces that it has signed a term loan of approximately $4 million (2.10 million GBP) with Bank and Clients PLC ("B&C" based in the UK. Under certain conditions, the loan could be increased up to $10 million (5.25 million GBP). All amounts are in Canadian dollars unless otherwise stated. NTB.TO: 1.26 (+0.01), NEPT: 0.98 (+0.03)
Neptune Announces Preliminary Q4 Results
Marketwired - Tue Apr 05, 6:31AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company"
(NASDAQ: NEPT)(TSX: NTB), announces preliminary selected results for the fourth quarter ended February 29, 2016. All amounts in Canadian dollars. The financial information in this press release excludes Acasti Pharma. ACST: 1.35 (+0.02), NTB.TO: 1.26 (+0.01), NEPT: 0.98 (+0.03)
Nasdaq Grants Acasti Cure Period to Regain Compliance with Audit Committee Membership Requirements
Marketwire Canada - Fri Mar 25, 1:03PM CDT
Acasti Pharma Inc. ("Acasti" or the "Corporation"
(NASDAQ:ACST)(TSX VENTURE:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of hypertriglyceridemia, announces that on March 22, 2016, it received a Nasdaq Deficiency Letter (the "Nasdaq Letter" confirming that the Corporation is no longer in compliance with Nasdaq Listing Rule 5605, requiring a company's audit committee to be comprised of at least three independent directors. Following the resignation of several board members on February 29, 2016, Acasti's Audit Committee is currently comprised of two independent directors. ACST: 1.35 (+0.02), NTB.TO: 1.26 (+0.01), NEPT: 0.98 (+0.03), APO.VN: 1.720 (-0.060)
Acasti Announces Share-for-Debt
Marketwire Canada - Fri Feb 05, 4:30PM CST
Acasti Pharma Inc. ("Acasti" or the "Corporation"
(NASDAQ:ACST)(TSX VENTURE:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of hypertriglyceridemia, announces the issuance of fifty thousand class A common shares as part of a settlement agreement executed on February 5, 2016. ACST: 1.35 (+0.02), NTB.TO: 1.26 (+0.01), NEPT: 0.98 (+0.03), APO.VN: 1.720 (-0.060)
Neptune Acquires Biodroga, Creating New Growth Platform
GlobeNewswire - Thu Jan 07, 6:07PM CST
-- Acquires privately held Biodroga, a leading turnkey dietary supplement solution provider with TTM revenues of $22M CDN
NTB.TO: 1.26 (+0.01), NEPT: 0.98 (+0.03)
Neptune to Hold Conference Call to Discuss Third Quarter Results
GlobeNewswire - Tue Jan 05, 6:50AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"
(NASDAQ:NEPT) (TSX:NTB), announces that it will be holding a conference call on January 13, 2016 at 8:30 AM (ET) to discuss its results for the third quarter ended November 30, 2015. NTB.TO: 1.26 (+0.01), NEPT: 0.98 (+0.03)
BUYINS.NET: PRU, RLH, CTCT, NEPT, PAC, HIMX Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Dec 03, 2:42AM CST
November 27, 2015
RLH: 6.39 (-0.01), PRU: 79.49 (+0.65), HIMX: 10.51 (+0.28), NEPT: 0.98 (+0.03), PAC: 101.06 (+1.59), CTCT: 32.01 (+1.39)
Neptune Provides Business Update
GlobeNewswire - Fri Nov 06, 8:21AM CST
-- Cash levels growing - expect nutraceutical Q3 cash balance of $4.5 - $5.0 million
NTB.TO: 1.26 (+0.01), NEPT: 0.98 (+0.03)
BUYINS.NET: NEPT, SBH, AIMC, CVLT, MHH, BIB Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Fri Oct 23, 8:02AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Neptun SA (NASDAQ:NEPT), Sally Beauty Holdings Inc (NYSE:SBH), Altra Holdings Inc (NASDAQ:AIMC), CommVault Systems Inc (NASDAQ:CVLT), Mastech Holdings Inc (NYSE:MHH), ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
BIB: 45.81 (-0.22), SBH: 27.71 (+0.30), MHH: 7.72 (+0.07), CVLT: 52.25 (+0.13), AIMC: 28.72 (+0.50), NEPT: 0.98 (+0.03)
(0)
(0)